

Rhythm Biosciences Limited
Appendix 4E
Preliminary final report

1. Company details

Name of entity:	Rhythm Biosciences Limited
ABN:	59 619 459 335
Reporting period:	For the year ended 30 June 2022
Previous period:	For the year ended 30 June 2021

2. Results for announcement to the market

		2022	2021
		\$	\$
Other income from ordinary activities	Up 118%	2,452,371	1,122,480
Loss from ordinary activities after tax attributable to the owners of Rhythm Biosciences Limited	Up 33% to	(8,793,521)	(6,612,148)
Comprehensive loss for the year attributable to the owners of Rhythm Biosciences Limited	Up 33% to	(8,793,521)	(6,612,148)

Dividends

There were no dividends paid, recommended or declared during the financial year.

Comments

The loss for the consolidated entity after providing for income tax was \$8,793,521. Comments on activities during the year are included in the Chairman's Letter and Managing Director and Chief Executive Officer's Report in the Annual Report attached. It should be noted that both Other income and the Loss from ordinary activities has been positively impacted by the Company lodging its Research & Development (R&D) tax offset claim. A further claim is expected to be lodged for FY2022 in the near term. This refundable tax offset for eligible R&D activities is expected to be received before the end of CY2022.

3. Net tangible assets

	Reporting period	Previous period
	Cents	Cents
Net tangible assets per ordinary security	<u>3.16</u>	<u>0.62</u>

4. Control gained over entities

In the United States, IchorDX, Inc., was incorporated on 2 July 2021 as a 100% owned subsidiary.

5. Loss of control over entities

Not applicable.

6. Details of associates and joint venture entities

Not applicable.

Rhythm Biosciences Limited
Appendix 4E
Preliminary final report

7. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements have been audited and an unqualified opinion has been issued.

8. Attachments

Details of attachments (if any):

The Annual Report of Rhythm Biosciences Limited for the year ended 30 June 2022 is attached.

9. Signed



Glenn Gilbert
Managing Director and CEO

Date: 29 August 2022

For personal use only